For more than a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that "Bromo- and ...

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve ...

Many cancer survivors live with the worry that their cancer might come back. This “recurrence” occurs when cancer cells hide somewhere in the body – like in the bone marrow – and start growing again, ...

BD200 demonstrated superior uptake and cellular cytotoxicity when compared to approved drugs targeting either Trop-2 or ...

A new study details the development of a nanoparticle-based system that delivers concentrated chemotherapy specifically to cancer cells and not normal cells, potentially allowing clinicians to ...

New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing ...